Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 1.17%

Alnylam Pharmaceuticals reported a wider-than-expected loss per share but did not provide revenue figures. The stock reacted negatively, declining by 1.17%, indicating that investors may have been looking for stronger performance or clearer guidance. The lack of additional context from management may have contributed to the stock's downward movement.